货号 | 14706-5mg |
描述 | Vandetanib is a broad spectrum, orally available kinase inhibitor that targets primarily tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with IC50 values in the nanomolar range.1,2 It also potently blocks non-receptor tyrosine kinases, including ABL, RET, and SRC, as well as several serine/threonine kinases.3,4 Primarily because of its effects on receptor tyrosine kinases like VEGFR and EGFR, vandetanib inhibits angiogenesis, cell growth, and metastasis and is effective against certain forms of cancer.4,5 |
别名 | Caprelsa®;CH 331;Zactima;ZD 6474; |
供应商 | Cayman |
应用文献 | |
1.Hennequin, L.F.,Stokes, E.S.E.,Thomas, A.P., et al. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. Journal of Medicinal Chemistry 45, 1300-1312 (2002). 2.Kiselyov, A.S.,Piatnitski, E.,Milligan, D., et al. 1H-1,2,4-Triazol-3-yl-anilines: Novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2. Chem.Biol.Drug Des. 69, 331-337 (2007). 3.Davis, M.I.,Hunt, J.P.,Herrgard, S., et al. Comprehensive analysis of kinase inhibitor selectivity. Nat.Biotechnol. 29(11), 1046-1051 (2011). 4.Morabito, A.,Piccirillo, M.C.,Falasconi, F., et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: Current status and future directions. Oncologist 14, 378-390 (2009). 5.Ton, G.N.,Banaszynski, M.E. and Kolesar, J.M. Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. American Journal of Health-System Pharmacy 70, 849-855 (2013). | |
运输条件 | Room temperature in continental US; may vary elsewhere |
存放说明 | -20 |
纯度 | ≥98% |
计算分子量 | 475.4 |
分子式 | C22H24BrFN4O2 |
CAS号 | 443913-73-3 |
稳定性 | ≥ 2 years |
本官网所有报价均为常温或者蓝冰运输价格,如有产品需要干冰运输,需另外加收干冰运输费。 |